Ramos et al. [30] probes the prognostic potential of systemic inflammatory response markers in resectable lung cancer, with albumin-to-globulin ratio (AGR), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) and emerging as key indicators. This evidence concerns the gene ALB and lung carcinoma.